Truffle Eyes A Dozen Investments With New BioMedtech Fund
Truffle Capital has raised $102m for its new institutional venture fund, nearly half of its $240m target, and is set to create and finance a dozen biotech and medtech companies with the capital.
You may also be interested in...
French VC firm Truffle Capital has raised €250 million ($278m) for its new BioMedTech fund. The capital will be used to create 12 new medtech companies.
Medical has gained a worldwide exclusive license from Harvard University for a catheter-based tool to repair tissue defects in difficult-to-reach organs.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.